Verastem(VSTM)盘前涨超26% 卵巢癌药物申请已被FDA接受 并获得优先审查

金吾财讯
31 Dec 2024

金吾财讯 | Verastem(VSTM)盘前涨超26%,截至发稿,报4.66美元。消息面上,公司周一表示,美国食品和药物管理局已接受用于复发性低级浆液性卵巢癌的avutometinib与defactinib联合治疗的新药申请,该患者至少接受过一次系统治疗,并且具有KRAS突变。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10